Consult a Healthcare Provider If your healthcare provider determines that Semaglutide or Liraglutide is suitable for your needs, they will prescribe the medication
M.BreinholtC
Liraglutide was approved in Europe in 2009 and by the FDA in January 2010 as Victoza ( [114] ) ( [115] )
Gonzlez, Universidad Autnoma de Nuevo Len, Monterrey, 64460, Mxico 11 Ted Rogers Center for Heart Research, Canada 12 Service of Endocrinology, Diabetes, Nutrition and Patient Therapeutic Education, Geneva University Hospitals, Geneva, Switzerland 13 Newbridge Surgery, Bath, UK 14 Sydney School of Public Health, The University of Sydney, Sydney, Australia 15 Centre for Kidney Research, The Childrens Hospital at Westmead, Sydney, Australia 16 Renal Division, Ghent University Hospital, Belgium 17 University of California Davis, USA 18 Department of Endocrinology, Clinic of Medicine, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway 19 K kumc gmail.com Abstract Clinical question What are the benefits and harms of sodium-glucose cotransporter 2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists when added to usual care (lifestyle interventions and/or other diabetes drugs) in adults with type 2 diabetes at different risk for cardiovascular and kidney outcomes
